Amneal Pharmaceuticals, Inc.
AMRXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for AMRX. That does not mean none is planned.
Get an email about AMRX's next catalysts
Track Amneal Pharmaceuticals (AMRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 2 past
No catalysts found.
How AMRX's past catalysts played out
Market Overview
Stock performance and key metrics
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
WebsitePhenazopyridine Hydrochloride Tables, USP
Uncomplicated Urinary Tract Infections
Testosterone Topical Gel, Metered Pump
Primary Hypogonadism
Estradiol Vaginal
Atrophic Vaginitis Due to Menopause
Asenapine Sublingual
Schizophrenia
Imatinib Mesylate
Chronic Myeloid Leukemia
Phenazopyridine Hydrochloride
Pain
Test - Bimatoprost Ophthalmic
Glaucoma, Open-Angle
Diclofenac Sodium Topical
Osteoarthritis
Mometasone Furoate Nasal
Seasonal Allergic Rhinitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Phenazopyridine Hydrochloride Tables, USP | Phase 3 | Uncomplicated Urinary Tract Infections | - | - |
Testosterone Topical Gel, Metered Pump | Phase 3 | Primary Hypogonadism | - | - |
Estradiol Vaginal | Phase 3 | Atrophic Vaginitis Due to Menopause | - | - |
Asenapine Sublingual | Phase 3 | Schizophrenia | - | - |
Imatinib Mesylate | Phase 3 | Chronic Myeloid Leukemia | - | - |
Phenazopyridine Hydrochloride | Phase 3 | Pain | - | - |
Test - Bimatoprost Ophthalmic | Phase 3 | Glaucoma, Open-Angle | - | - |
Diclofenac Sodium Topical | Phase 3 | Osteoarthritis | - | - |
Mometasone Furoate Nasal | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Frequently asked questions
What is in Amneal Pharmaceuticals, Inc.'s drug pipeline?β
CatalystAlert tracks 9 drug candidates in Amneal Pharmaceuticals, Inc.'s (AMRX) pipeline across Phase 3. Its lead program is Asenapine Sublingual (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amneal Pharmaceuticals, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Amneal Pharmaceuticals, Inc. (AMRX) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track AMRX biotech catalysts?β
Add AMRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amneal Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
